Closing The Spread: 340B Providers Face Sharp Cuts Under Medicare Proposal

Medicare payments to hospitals for drugs provided under the 340B program would be reduced to average sales price (ASP) minus 22.5%, which CMS believes is more closely aligned with the discounted price obtained by the providers.

Dollar sign made with drug pills

The Centers for Medicare and Medicaid Services plans to significantly lower Medicare Part B payments to hospitals for prescription drugs provided on an outpatient basis under the 340B drug discount program to help lower costs to the program and for beneficiaries.

The agency proposes reducing Medicare's drug payments to providers from the current average sales price (ASP) plus 6% to ASP minus 22.5% in its 2018 Hospital Outpatient Prospective Payment System...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Medicare

GLP-1 Pricing ‘Paradigm Shift’ Possible, But Would It Meet Trump’s MFN Goals?

 
• By 

For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices.

Rocky Rollout Spells Trouble for Medicare Prescription Payment Plan

 

Enrollment in the new Medicare Prescription Payment Plan was lower than expected in the first year and well below CMS expectations, and invoicing data indicates members are slow to pay.

Will International Prices Influence Medicare Price Negotiation?

 
• By 

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.

More from Government Payers

HHS Negotiating With Manufacturers On Most Favored Nation Drug Pricing

 
• By 

MFN policy would would apply to all single source drugs in all insurance markets, according to HHS release. Secretary Robert F. Kennedy Jr. said the department is discussing the plan with drug sponsors.

Will International Prices Influence Medicare Price Negotiation?

 
• By 

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.